BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 30
• 31

• 

  Business

  Ginkgo Scores Another Big Partner in Merck Biocatalyst Deal

  Ginkgo Bioworks partnered with Merck on engineered enzymes for use as biocatalysts for Merck’s active pharmaceutical ingredient (API) manufacturing programs.

  October 11, 2022

   · 

  4 min read

   · 

  Mark Terry
• 

  Drug Development

  Dupixent Shows Promise as First Treatment for Childhood EoE

  Data from an ongoing Phase III trial showed Sanofi/Regeneron’s Dupixent can induce histological disease remission in young EoE patients aged 1–11.

  October 11, 2022

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Deals

  PureTech and Nektar Call Off Rumored Merger

  Last week, rumors spread that PureTech Health was preparing to merge with Nektar Therapeutics. Now the deal, never officially announced, has been called off.

  October 11, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Albireo Drug Makes “Profound” Difference in Rare Alagille Syndrome

  Albireo Pharma reported dazzling Phase III ASSERT data of Bylvay for Alagille syndrome (ALGS). The company is headed to U.S. and European regulators with expectations of regulatory filings in Q1 of 2023.

  October 11, 2022

   · 

  2 min read

   · 

  Mark Terry
• 

  Career Advice

  Why Hiring Managers Must Act Differently to Stay Competitive in Today’s Job-Seeker’s Market

  In the wake of a global pandemic and economic downturn, the hiring market has turned on its head. BioSpace spoke with PharmaLogics Recruiting to learn how employers can stay competitive.

  October 11, 2022

   · 

  4 min read

   · 

  Rosemary Scott
• 

  Business

  BIO Taps King as Interim CEO after McMurry-Heath Ousting

  Biotechnology Innovation Organization, the world’s largest science and public advocacy organization, announced Monday it has tapped Rachel King to serve as interim President and CEO.

  October 11, 2022

   · 

  2 min read

   · 

  Rosemary Scott
• 

  Business

  Ascidian Nets $50M to Rewrite RNA in Stargardt Disease and Beyond

  With $50 million in backing from Apple Tree Partners, Ascidian Therapeutics launches Tuesday with technology that allows for the treatment of some diseases through rewriting of RNA.

  October 11, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  New Approaches Emerge for a Prevalent Nemesis: Gout

  Incidence of gout - the most common inflammatory arthritis in the world - are on the rise. Arthrosi Therapeutics, Synlogic, Atom Bioscience and Ginkgo Bioworks are on the case with novel new approaches.

  October 11, 2022

   · 

  5 min read

   · 

  Gail Dutton
• 

  Business

  ImmunityBio Backslides while Rigel and Amneal also Reveal Job Cuts (Updated)

  ImmunityBio is laying off 38 employees at its Dunkirk site in New York, Amneal will shutter a Long Island facility and Rigel culls 30 employees following wAIHA regulatory decision.

  October 11, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Neumora Raises Additional $112M to Advance Neuro Pipeline (Updated)

  One year after raising $500 million, Neumora Therapeutics secured an additional $112 million in a Series B financing round to support the advancement of its neuroscience portfolio.

  October 11, 2022

   · 

  3 min read

   · 

  Alex Keown